|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||100.40 - 101.18|
|52 Week Range||58.59 - 101.18|
|Beta (3Y Monthly)||1.44|
|PE Ratio (TTM)||13.80|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Celgene Corporation (CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001. The study evaluated the efficacy and safety of investigational therapy CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia (AML) who achieved first complete response (CR) or complete response with incomplete blood count recovery (CRi) with induction chemotherapy (with or without consolidation).
Data to be presented include analyses of long-term efficacy and safety of ozanimod in adults with relapsing forms of multiple sclerosis and effects on biomarkers of disease activit
THOUSAND OAKS, Calif., Aug. 26, 2019 /PRNewswire/ -- Amgen (AMGN) announced today that it has entered into an agreement with Celgene Corporation (CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (BMY) to acquire worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities, for $13.4 billion in cash, or approximately $11.2 billion, net of the present value of $2.2 billion in anticipated future cash tax benefits.
Hach Rose Schirripa & Cheverie LLP, a nationally recognized plaintiffs’ law firm dedicated to handling complex litigation, announced earlier this week that it has reached a $55 million settlement with Celgene Corporation (CELG) in a long-running class action, In re Thalomid and Revlimid Antitrust Litigation. The settlement is one of the largest pharmaceutical settlements on behalf of end payors (consumers, insurers, union health and welfare funds, municipalities, and others) in an antitrust case in the last decade. Hach Rose Schirripa & Cheverie filed this class action suit in 2014, alleging that Celgene had monopolized the market for two drugs, Thalomid and Revlimid, which are primarily used to treat multiple myeloma, a cancer that forms in the blood. Specifically, the plaintiffs alleged that Celgene kept generic versions of these two drugs off the market, in violation of state and federal antitrust laws. Throughout the litigation, the end payor plaintiffs asserted that prices for the two drugs were higher than they would have been in a competitive market.
Block & Leviton LLP, a nationwide plaintiffs’ law firm dedicated to handling complex class action litigation, announced today that it has reached a $55 million settlement with Celgene Corporation (CELG) in a long-running class action case, In re Thalomid and Revlimid Antitrust Litigation. The settlement represents one of the largest pharmaceutical settlements in an antitrust case brought on behalf of end payors (patients, health and welfare funds, insurers, and others). Filed in 2014, the plaintiffs in this class lawsuit alleged that Celgene monopolized the market for two drugs, Thalomid and Revlimid, which are primarily used to treat multiple myeloma, a form of blood cancer. Specifically, the plaintiffs alleged that Celgene kept generic versions of these two drugs off the market, in violation of various federal and state antitrust laws. Throughout the litigation, the end payor plaintiffs asserted that prices for Thalomid and Revlimid were higher than they would have been in a competitive market.
Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced an update on its strategic collaboration with Celgene Corporation (CELG), originally established in July 2016. Under the terms of a new license agreement, Celgene has licensed worldwide rights to JTX-8064, a highly-selective, potential first-in-class antibody that targets the LILRB2 receptor on macrophages.
Bristol-Myers Squibb Company (BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (CELG). The Company remains actively engaged in discussions with the U.S. Federal Trade Commission (“FTC”) on the FTC’s continued review of the proposed transaction. To allow the transaction to close on a timely basis in light of concerns expressed by the FTC, the Company is planning the divestiture of OTEZLA® (apremilast).
Leoplus USA is developing Duet, a device and app which aims to support communications between people with MS and their care partners to help improve patients' disease management outcomes. "We know communication within families affected by multiple sclerosis can be challenging. Duet is an innovative way to create connections with those you love," said Tim Coetzee, Ph.D., Chief Advocacy, Services and Research Officer at the National Multiple Sclerosis Society, who served as chair of the judging panel.
Celgene Corporation (CELG) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application for ozanimod for the treatment of people with relapsing forms of multiple sclerosis (RMS) in the United States. The European Medicines Agency (EMA) also accepted for review the Marketing Authorization Application for ozanimod for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) in the European Union.
Bristol-Myers Squibb Company (BMY) today announced the future leadership team of the combined company effective upon completion of the company’s pending merger with Celgene Corporation (CELG). The company is evolving key aspects of its R&D and Commercialization structure to drive the continued growth of a highly successful marketed portfolio, maximize the six near-term launch opportunities and deliver the value of the combined pipeline, all guided by its continued mission of serving patients with serious disease.
Data show the potential of investigational anti-CD19 chimeric antigen receptor T-cell therapy in patients with previously treated blood cancers, including those with high-risk dise
Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics License Application (BLA) for luspatercept, an investigational erythroid maturation agent, for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions, and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions. The FDA has granted Priority Review to this BLA for the evaluation of the beta-thalassemia indication and set a Prescription Drug User Fee Act (PDUFA), or target action, date of December 4, 2019.
Celgene Corporation (CELG) announced an updated analysis of data from the Phase 2 JAKARTA2 clinical study demonstrating clinically meaningful response rates with investigational fedratinib in patients with myelofibrosis previously treated with ruxolitinib. This updated analysis of fedratinib employed intent-to-treat (ITT) principles and utilized a narrower definition of ruxolitinib relapsed, refractory, or intolerant patients. Results were shared in a poster presentation today at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Celgene Corporation (CELG) today announced the first clinical results evaluating iberdomide (CC-220) in combination with dexamethasone in patients with relapsed and refractory multiple myeloma from the ongoing phase 1/2 CC-220-MM-001 study during an oral presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The results included preliminary safety and efficacy data from the ongoing multicenter, open-label, dose-escalation study, which aims to determine the maximum tolerated dose and the recommended phase 2 dose of iberdomide in combination with dexamethasone. Iberdomide is Celgene’s proprietary cereblon E3 ligase modulator (CELMoD®) compound with enhanced tumoricidal and immune stimulatory effects demonstrated in preclinical studies.
Approval marks the first chemotherapy-free combination regimen for patients who have relapsed or did not respond to previous treatment
Celgene Corporation (CELG) and the Multiple Sclerosis Association of America (MSAA) today announced the launch of a new campaign, MS MindShift: A New View of MS, a national initiative that provides new perspective on multiple sclerosis (MS). The campaign aims to educate about the critical role the brain plays in the disease and what people living with MS can do to keep their brain as healthy as possible, for as long as possible. To bring this new perspective on MS closer to the community, the campaign will host engaging, educational events in various cities.
The European Commission has approved two of Celgene’s IMiD®-based combination regimens:
Presentations include innovative cancer research, including novel CAR T technology, as well as key disease areas, including myelofibrosis and multiple myeloma